

## Product datasheet for **TL302539V**

### PEX16 Human shRNA Lentiviral Particle (Locus ID 9409)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	PEX16 Human shRNA Lentiviral Particle (Locus ID 9409)
Locus ID:	9409
Synonyms:	PBD8A; PBD8B
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	PEX16 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<a href="#">NM_004813</a> , <a href="#">NM_057174</a> , <a href="#">NM_004813.1</a> , <a href="#">NM_004813.2</a> , <a href="#">NM_057174.1</a> , <a href="#">NM_057174.2</a> , <a href="#">BC004356</a> , <a href="#">BC004356.1</a> , <a href="#">BC000467</a> , <a href="#">BM746616</a> , <a href="#">NM_057174.3</a>
UniProt ID:	<a href="#">Q9Y5Y5</a>
Summary:	The protein encoded by this gene is an integral peroxisomal membrane protein. An inactivating nonsense mutation localized to this gene was observed in a patient with Zellweger syndrome of the complementation group CGD/CG9. Expression of this gene product morphologically and biochemically restores the formation of new peroxisomes, suggesting a role in peroxisome organization and biogenesis. Alternative splicing has been observed for this gene and two variants have been described. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).